NSCLC STAGE IV
Clinical trials for NSCLC STAGE IV explained in plain language.
Never miss a new study
Get alerted when new NSCLC STAGE IV trials appear
Sign up with your email to follow new studies for NSCLC STAGE IV, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo shows promise for tough lung cancer
Disease control CompletedThis study tested a combination of two drugs, bemcentinib and pembrolizumab, in 99 people with advanced lung cancer that had already been treated. The goal was to see if the combo could shrink tumors. Participants were divided into groups based on their prior treatments. The stud…
Matched conditions: NSCLC STAGE IV
Phase: PHASE2 • Sponsor: BerGenBio ASA • Aim: Disease control
Last updated May 26, 2026 05:10 UTC
-
New hope for Drug-Resistant lung cancer: combo therapy shows promise
Disease control CompletedThis study tested a combination of chemotherapy drugs (platinum and pemetrexed) plus an immunotherapy drug (atezolizumab), with or without another drug (bevacizumab), in 150 people with advanced non-squamous lung cancer that has specific gene changes (EGFR, ALK, or ROS1) and has …
Matched conditions: NSCLC STAGE IV
Phase: PHASE2 • Sponsor: Centre Francois Baclesse • Aim: Disease control
Last updated May 26, 2026 05:03 UTC
-
New approach uses targeted therapy to control metastatic lung cancer
Disease control CompletedThis study looked at whether a targeted treatment called local ablative therapy (LAT) can help control metastatic non-small cell lung cancer (NSCLC) when a blood test shows rising levels of cancer DNA (minimal residual disease or MRD). 37 participants received LAT to all visible …
Matched conditions: NSCLC STAGE IV
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New scan may predict immunotherapy success in lung cancer
Knowledge-focused CompletedThis study tested a new type of PET scan that looks for a protein called PD-L1 in tumors. The goal was to see if this scan could predict which patients with advanced lung cancer would benefit from the immunotherapy drug nivolumab. Eighty patients received the scan before starting…
Matched conditions: NSCLC STAGE IV
Phase: NA • Sponsor: The Netherlands Cancer Institute • Aim: Knowledge-focused
Last updated May 22, 2026 13:50 UTC